Does the Grade of Diastolic Dysfunction Predict Short-term Outcomes Of Acute Ischemic Stroke Patients? (P3.075)

Objective: To determine if diastolic dysfunction (DD) in acute ischemic stroke (AIS) patients is associated with differences in short-term outcomes. Background: DD is a common finding in patients who suffer AIS. Data describing the consequences of DD in AIS patients are lacking. Design/Methods: Patients diagnosed with AIS presenting to our center between 6/2008-5/2014 and assessed by transthoracic echocardiogram (TTE) were identified from our prospective registry. Patients with in-hospital stroke or with systolic dysfunction (EF 2) and unfavorable discharge (other than home or inpatient rehabilitation) were investigated by degree of DD. Results: Of the 1,583 patients screened, 691 met criteria (median age 65 years; 67[percnt] black; 46[percnt] female). Of these, 147 (21.2[percnt]) had no DD, 478 (76.48[percnt]) had grade 1 DD, and 66 (12.13[percnt]) had grades 2-4 DD. After adjustment for covariates, no differences in outcomes were detected comparing no DD with DD grade 1 patients. Multivariate analysis adjusting for age, NIHSS at baseline, glucose at baseline, and tPA administration, found that patients with DD grades 2-4 were over four times more likely to experience in-hospital mortality (OR=4.32, 95[percnt] CI 1.57-11.90, p=0.005) than patients with grade 1 DD and were five times more likely to experience in-hospital mortality (OR=5.04, 95[percnt] CI 1.23-20.67, p=0.025) than patients with no DD. Conclusions: After adjustment for covariates, DD grade 1 was not associated with death or poor functional outcome. Advanced grade of DD, however, was associated with a higher risk of in-hospital mortality. Study supported by: none Disclosure: Dr. Valmoria has nothing to disclose. Dr. Monlezun, Jr has nothing to disclose. Dr. Elegante has nothing to disclose. Dr. Dowell has nothing to disclose. Dr. Warren has nothing to disclose. Dr. George has nothing to disclose. Dr. El-Khoury has nothing to disclose. Dr. Martin-Schild has received personal compensation for activities with Genentech as a speakers bureau participant.